Showing results (1-10 of 94) with videos related to
Sort By:
Pageof 10
Current Pharmaceutical Design|August 21, 2010
Nitrogen-containing bisphosphonates and cancer immunotherapyP Clézardin, M MassaiaBulletin Du Cancer|July 3, 2010
[Antitumor properties of the bisphosphonate zoledronate and potential therapeutic implications in the clinic]P ClézardinPresse Medicale (Paris, France : 1983)|April 4, 2000
[Bone hyperresorption in bone metastases]P ClézardinJoint Bone Spine|April 25, 2000
Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysisP Clézardin, J Gligorov, P DelmasLeukemia & Lymphoma|March 1, 1995
T cells in multiple myeloma: is this a reliable population to count on as antitumor effector cells?M Massaia, A PileriMolecular Medicine Today|November 14, 1997
Idiotypic vaccination in B-cell malignanciesA Bianchi, M MassaiaJournal of Clinical & Laboratory Immunology|February 1, 1984
Soluble factor(s) released by Concanavalin A activated lymph node lymphocytes induce proliferation and maturation of chronic lymphocytic leukaemia (CLL) B lymphocytesL Matera, M Massaia, L PegoraroJournal of Cellular Biochemistry|October 28, 1999
Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chainB Merle, L Durussel, P D Delmas, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 7, 2000
Platelet-osteosarcoma cell interaction is mediated through a specific fibrinogen-binding sequence located within the N-terminal domain of thrombospondin 1C Voland, C M Serre, P Delmas, et al.Seminars in Hematology|February 16, 1999
Idiotypic vaccination as therapy for multiple myelomaL W Kwak, K Thielemans, M MassaiaPageof 10